PARP Inhibitor activity correlates with slfn11 expression and demonstrates synergy with temozolomide in small cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Autocrine Communication
  • Carcinoma, Non-Small-Cell Lung
  • Drug Resistance, Neoplasm
  • Proto-Oncogene Proteins B-raf
  • Receptor, Epidermal Growth Factor

abstract

  • SLFN11 is a relevant predictive biomarker of sensitivity to PARP inhibitor monotherapy in SCLC and we identify combinatorial therapy with TMZ as a particularly promising therapeutic strategy that warrants further clinical investigation. Clin Cancer Res; 23(2); 523-35. ©2016 AACR.

publication date

  • January 15, 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5241177

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-16-1040

PubMed ID

  • 27440269

Additional Document Info

start page

  • 523

end page

  • 535

volume

  • 23

number

  • 2